Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  De Luca, Andrea ^a   Hamers, Raphael L ^b   Schapiro, Jonathan M ^c  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

antiretroviral therapy; HIV 1 drug resistance; resource limited settings; sequencing

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DEVELOPING COUNTRY; DRUG DOSE SEQUENCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECONOMIC ASPECT; GENE MUTATION; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; RESOURCE LIMITED SETTING; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; HIV-1 DRUG RESISTANCE; RESOURCE-LIMITED SETTINGS; SEQUENCING;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; POVERTY; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 84878327935     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit109     Document Type: Article

References (30)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to ART against HIV in resource-limited settings. Lancet 2006; 368: 505-10.
2. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997; 176:398-405.
3. Hamers RL, Sigaloff KC, Wensing AM, et al.; PharmAccess African Studies to Evaluate Resistance. Patterns of HIV-1 drug-resistance after first-line ART failure in six sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-9.
4. Wallis CL, Mellors JW, Venter WD, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
5. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
6. Dlamini JN, Hu Z, Ledwaba J, et al. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efa-virenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2011; 58:304-8.
7. Lockman S, Hughes M, Sawe F, et al. Nevirapine-versus lopinavir/rito-navir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 2012; 9:e1001236. Epub 2012 Jun 12.
8. Ajose O, Mookerjee S, Mills EJ, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-38.
9. Naeger LK, Struble KA. Effect of baseline protease genotype and phe-notype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006; 20:847-53.
10. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of daru-navir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
11. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-78.
12. Maiga AI, Fofana DB, Cisse M, et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. J Antimicrob Chemother 2012; 67:2943-8.
13. HIV drug resistance database. Stanford, CA: Stanford University. http://hivdb.stanford.edu/cgi-bin/PI-Form.cgi. Accessed 27 February 2013.
14. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monother-apy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-52.
15. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ri-tonavir (DRV/r)monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13:398-405.
16. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir mono-therapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patients. AIDS 2008; 22:385-93.
17. Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir mono-therapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345-54.
18. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs.: teno-fovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther 2012; 17:1351-61.
19. Gilks CF, Walker AS, Dunn DT, et al. Lopinavir/ritonavir monotherapy after 24cweeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther 2012 Jul 19. doi:10.3851/IMP2253.
20. Delaugerre C, Flandre P, Chaix ML, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-9.
21. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11:825-33.
22. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910-8.
23. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371: 1443-51.
24. Wallis C, Papthanasopoulos M, Fox M, et al. Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy. Antivir Ther 2012; 17:313-20.
25. Prosperi MC, Mackie N, Di Giambenedetto S, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011; 66:1886-96.
26. Hamers RL, Sawyer AW, Tuohy M, et al.; ART-A Consortium. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26: 1663-72.
27. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretrovi-ral drug resistance. N Engl J Med 2011; 365:637-46.
28. von Wyl V, Cambiano V, Jordan MR, et al. Cost-effectiveness of tenofo-vir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One 2012; 7:e42834.
29. Lockman S, Hughes MD, McIntyre J, et al. OCTANE A5208 Study Team. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-509.
30. Ciaranello AL, Lockman S, Freedberg KA, et al. CEPAC-International and OCTANE Investigators. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 2011; 25:479-92.